

BRAND INSTITUTE IS PROUD TO HAVE PARTNERED ON THE FOLLOWING BRAND NAMES RECENTLY APPROVED BY HEALTH CANADA

PLEASE BE SAFE AND THANK YOU FOR MAKING BRAND INSTITUTE THE WORLD'S #1 NAMING COMPANY!

June 12, 2020 KYNMOBI™ (apomorphine HCl) sublingual film	June 12, 2020  Odomzo® (sonidegib) capsules 200mg	June 10, 2020  Duobrii® (halobetasol propionate and tazarotene) Lotion 0.01% / 0.045%
June 5, 2020  TUKYSA™ tucatinib 50 mg 150 mg tablets	June 1, 2020 Enspryng satralizumab	April 21, 2020  ZIEXTENZO® (pegfilgrastim-bmez)
April 16, 2020 Nivestym™ (filgrastim-aafi) Injection	April 15, 2020  UCERIS® (budesonide) extended release tablets	April 15, 2020 NDC 73154-050-60  IBSRELA® (tenapanor) tablets
March 18, 2020 Vocabria cabotegravir	March 18, 2020  CABENUVA cabotegravir 200 mg/mL; rilpivirine 300 mg/mL extended-release injectable suspensions	March 12, 2020 Beovu® (brolucizumab-dblb) Injection

DRUG SAFETY INSTITUTE (DSI) NAMING & LABELING EXPERT SPOTLIGHT



Scott Sawler, B.Sc., LL.B., LL.M., M.B.A.


President, Canadian Regulatory Affairs

Mr. Sawler joined Brand Institute's regulatory subsidiary, Drug Safety Institute (DSI) - Ottawa as Managing Director, Canadian Regulatory Affairs in 2017 and in 2018 was promoted to President, Canadian Regulatory Affairs. Prior to joining DSI, he was Director General (DG) of Health Canada's Marketed Health Products Directorate (MHPD), which is responsible for reviewing and approving proposed proprietary (brand) names; conducting risk/benefit assessments of marketed health products; overseeing the advertising regulatory requirements of health products; providing policies to effectively regulate marketed health products etc.

Prior to this, Mr. Sawler was the DG of Health Canada's Natural and Non-prescription Health Product Directorate where he led the program through a transitional period. He re-established its strategic vision, overhauled its policies and streamlined management systems to put the program back on track. Mr. Sawler also has significant experience as an executive and counsel in clinical trial management, government, legal and regulatory affairs. His clients included pharmaceutical companies, health professional associations, and non-governmental organizations.

Mr. Sawler earned his LL.M. from Osgoode Hall at York University, an M.B.A. from the University of Laval, an LL.B. from the University of Ottawa, and a B.Sc. in Chemistry from the University of New Brunswick.

BRAND INSTITUTE'S 2019 GLOBAL SHARE OF MARKET NAME APPROVALS



Corporate Headquarters

200 SE 1st Street 12th Floor Miami, FL 33131 Telephone: (305) 374-2500 Fax: (305) 374-2504 www.brandinstitute.com

BASEL +41 78-879-4619	BOSTON (781) 602-6044	CHICAGO (312) 475-9600	DALLAS (512) 369-9100	FRANKFURT +49 6196-400-966	LONDON +44 207-240-2200	LOS ANGELES (310) 830-6111	MIAMI (305) 984-6889	NEW YORK (212) 557-2100
OTTAWA (613) 482-1333	RALEIGH-DURHAM (919) 572-9311	ROCKVILLE (301) 984-1055	SAN FRANCISCO (415) 421-3200	SÃO PAULO +55 11 945-364-083	SEATTLE (206) 204-5111	SEOUL +82 6433-9555	TOKYO +81(03) 6861-7517	TORONTO (416) 622-5777